Characteristics of diabetic macular edema on optical coherence tomography may change over time or after treatment
Authors Sheu SJ, Lee YY, Horng YH, Lin HS, Lai WY, Tsen CL
Received 14 May 2018
Accepted for publication 11 July 2018
Published 26 September 2018 Volume 2018:12 Pages 1887—1893
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Editor who approved publication: Dr Scott Fraser
Shwu-Jiuan Sheu,1,2 Ying-Yen Lee,1 Yu-Harn Horng,1 Huey-Shyan Lin,3 Wei-Yu Lai,1 Chui-Lien Tsen1
1Department of Ophthalmology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan; 2Department of Ophthalmology, School of Medicine, National Yang-Ming University, Taipei, Taiwan; 3Department of Health-Business Administration, Fooyin University, Kaohsiung, Taiwan
Purpose: To investigate optical coherence tomography (OCT) characteristics in diabetic macular edema (DME) over time and after treatment.
Patients and methods: OCT morphological features in DME eyes treated with ranibizumab with at least 1 year of follow-up were retrospectively analyzed.
Results: Thirty-five eyes were included. From baseline to Month 12, mean visual gain was 7.2±13.6 letters and mean central retinal thickness reduction was 61.9±121.8 µm. Fovea-involving ellipsoid zone (EZ) disruption was significantly associated with final vision of <70 letters. Subretinal fluid at baseline was present only in eyes naïve to previous intravitreal pharmacotherapy and was related to better visual gain and fewer injections. Treatment-naïve eyes had shorter DME duration and less EZ damage.
Conclusion: DME characteristics on OCT may change over time or after treatment. Subretinal fluid may be associated with earlier change and less EZ damage in DME.
Keywords: diabetic macular edema, optical coherence tomography, OCT, subretinal fluid, SRF, vascular endothelial growth factor, VEGF
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]